A Turning Point in MASH
A billion-dollar acquisition, breakthrough clinical data, and a shifting scientific paradigm are pushing MASH out of the shadows and into a new era of metabolic medicine.
False
Advertisement
Related Content
Development & Clinical
Biopharma
Interviews
Musings from The Power List: Andres Sirulnik
October 5, 2026
4 min read
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
Development & Clinical
Cell & Gene
Interviews
Musings from The Power List: Fabian Gerlinghaus
October 1, 2026
3 min read
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
Cell & Gene
In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming
September 30, 2026
10 min read
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications
Cell & Gene
Industry News
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
September 30, 2026
2 min read
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort